BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 202,300 shares, a growth of 113.4% from the January 31st total of 94,800 shares. Based on an average daily volume of 373,300 shares, the short-interest ratio is currently 0.5 days. Approximately 5.9% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price objective on BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

Institutional Trading of BriaCell Therapeutics

Several large investors have recently modified their holdings of BCTX. Cantor Fitzgerald L. P. acquired a new position in shares of BriaCell Therapeutics during the 4th quarter valued at $32,000. Virtu Financial LLC acquired a new stake in shares of BriaCell Therapeutics in the 4th quarter valued at about $27,000. Finally, Vontobel Holding Ltd. increased its position in BriaCell Therapeutics by 37.5% in the 4th quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock valued at $62,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Stock Down 3.4 %

BCTX opened at $3.67 on Friday. BriaCell Therapeutics has a twelve month low of $3.33 and a twelve month high of $54.90. The company has a fifty day moving average of $5.77 and a 200-day moving average of $9.61. The stock has a market cap of $13.61 million, a PE ratio of -0.28 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings data on Monday, December 16th. The company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10). Sell-side analysts anticipate that BriaCell Therapeutics will post -2.45 EPS for the current fiscal year.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.